Mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-24. Anything still debated is marked as such rather than presented as settled.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
==== MeSH D06.472.317 – gastrointestinal hormones ==== MeSH D06.472.317.152 – cholecystokinin MeSH D06.472.317.152.700 – sincalide MeSH D06.472.317.350 – epidermal growth factor MeSH D06.472.317.400 – gastric inhibitory polypeptide MeSH D06.472.317.410 – gastrin-releasing peptide MeSH D06.472.317.413 – gastrins MeSH D06.472.317.413.593 – pentagastrin MeSH D06.472.317.413.800 – tetragastrin MeSH D06.472.317.469 – glucagon precursors MeSH D06.472.317.469.500 – enteroglucagons MeSH D06.472.317.469.500.500 – glucagon-like peptide 1 MeSH D06.472.317.525 – motilin MeSH D06.472.317.662 – peptide yy MeSH D06.472.317.800 – secretin MeSH D06.472.317.950 – vasoactive intestinal peptide
There are seven major structural groups, which are naphthoylindoles, naphthylmethylindoles, naphthoypyrroles, naphthylmethylindenes, phenylacetylindoles, cyclohexylphenols and classical cannabinoids respectively. Compared with classical cannabinoids, synthetic cannabinoids differ structurally. Some common synthetic cannabinoids are available in the market such as JWH-018, which is the most well-known naphthoylindole and JWH-250, a phenylacetylindole. They are sold under the brand name "Spice" as a recreational drug over the past decade.
Tafamidis was shown to have a greater effect when started earlier in the disease course, when milder disease was present, as amyloid deposits in the heart were lower. Acoramidis also showed a reduction in mortality in those with TTR amyloidosis compared to placebo and a reduction in hospitalizations related to heart disease. Tafamidis is considered a first line option for the treatment of TTR amyloidosis. Ten to 20% of those with ATTR amyloidosis required pacemakers, usually due to high degree atrioventricular blocks. Observational cohort data showed that biventricular pacing preserves left ventricular function, heart failure symptom scores and mitral regurgitation incidence compared to right ventricular pacing. Ventricular arrythmia are common in those with AL and ATTR amyloidosis and are associated with a higher risk of sudden cardiac death. However, the use of implantable cardioverter defibrillators remains questionable in cardiac amyloidosis (both light chain and ATTR amyloidosis) and a mortality benefit has not been consistently shown. Outside of standard indications for implantable cardioverter defibrillators for those with heart failure, specific benefits in those with cardiac amyloidosis are not well established. Two to 5% of people with ATTR amyloidosis experience sudden cardiac death.
Cost Reusability Battery life Ease of use; set-up, readability, download data, analysis, etc. Temperature range Number of measurements stored Accuracy and precision - degree of agreement of recorded temperature with actual Resolution Response time – the time required to measure 63.2% of the total difference between its initial and final temperature when subjected to a step function change in temperature; other points such as 90% are also used. shock and vibration resistance Water resistance – humidity, condensation, etc. Size, weight, mounting Certifications, calibrations, etc. Software Data export Data integration with other systems
April 15, 2010: Canada The union vote ratification for Stelco Lake Erie Works was confirmed with 88.5% voting in favor of the three-year deal; keeping the place open for industry. As a result, numerous jobs in the local area were saved by this "eleventh hour" action.
Sources: en.wikipedia.org
=== Eyes === A buffered PVP-I solution of 2.5% concentration can be used for prevention of neonatal conjunctivitis, especially if it is caused by Neisseria gonorrhoeae, or Chlamydia trachomatis. It is unclear whether PVP-I is more effective in reducing the number of cases of conjunctivitis in neonates over other methods. PVP-I appears to be very suitable for this purpose because, unlike other substances, it is also efficient against fungi and viruses (including HIV and Herpes simplex).
This new framework allows the user to mix models and take advantages of the efficiency of Bayesian MCMC analysis when dealing with different type of data (e.g. protein, nucleotide, and morphological). It uses the Metropolis-Coupling MCMC by default. MrBayes 3.2 was released in 2012. This version allows the users to run multiple analyses in parallel. It also provides faster likelihood calculations and allow these calculations to be delegated to graphics processing unites (GPUs). Version 3.2 provides wider outputs options compatible with FigTree and other tree viewers.
=== Heart disease, diabetes and quality of life === Blackburn also discovered that mothers caring for very sick children have shorter telomeres when they report that their emotional stress is at a maximum and that telomerase was active at the site of blockages in coronary artery tissue, possibly accelerating heart attacks. In 2009, it was shown that the amount of telomerase activity significantly increased following psychological stress. Across the sample of patients telomerase activity in peripheral blood mononuclear cells increased by 18% one hour after the end of the stress. A study in 2010 found that there was "significantly greater" telomerase activity in participants than controls after a three-month meditation retreat. Telomerase deficiency has been linked to diabetes mellitus and impaired insulin secretion in mice, due to loss of pancreatic insulin-producing cells.
2009: Chinese geneticist Zeng Fanyi and her research team published their experiment results proving that induced pluripotent stem cells can be used to generate whole mammalian bodies – in this case, live mice.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.